|
|
|
|
|
|
Sponsors and Collaborators: |
Emphycorp Cellular Sciences |
Information provided by: | Emphycorp |
ClinicalTrials.gov Identifier: | NCT00262613 |
In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent. Subjects with COPD are known to have inflammation in the lung, and often have bronchoconstriction. As such, these subjects typically are on multiple therapies, including steroid therapy. This trial will study the effect of inhaled sodium pyruvate on inflammation and lung function in COPD subjects over a six week period.
Condition | Intervention | Phase |
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: sodium pyruvate in 0.9% sodium chloride solution |
Phase II |
MedlinePlus related topics: | COPD (Chronic Obstructive Pulmonary Disease) |
Drug Information available for: | Sodium chloride Chlorides |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Long-Term Use of Inhaled Sodium Pyruvate for the Treatment of Chronic Obstructive Pulmonary Disease |
Estimated Enrollment: | 60 |
Study Start Date: | September 2004 |
Estimated Study Completion Date: | May 2006 |
Show Detailed Description |
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Connecticut | |||||
Hospital for Special Care | |||||
New Britain, Connecticut, United States, 06053 | |||||
Yale University School of Medicine | |||||
New Haven, Connecticut, United States, 06520-8057 |
Emphycorp |
Cellular Sciences |
Principal Investigator: | John J. Votto, D.O. | Hospital for Special Care |
Emphycorp Website 
  |
Study ID Numbers: | CSI-NII5-021 |
First Received: | December 6, 2005 |
Last Updated: | May 25, 2006 |
ClinicalTrials.gov Identifier: | NCT00262613 |
Health Authority: | United States: Food and Drug Administration |
|
|